Lei Pan1, Zhan-Sheng Jia, Lin Chen, En-Qing Fu, Guang-Yu Li. 1. Center of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, Shaanxi Province, China. panlei0225@sina.com
Abstract
AIM: To observe the effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients with hepatitis B virus (HBV) infection, and to compare the differences of liver function by two treatments of anti-tuberculosis. METHODS: Forty-seven TB patients with HBV infection and 170 TB patients without HBV infection were divided into HPBE(S) and HLAMKO treatment groups. Liver function tests before and after the treatments were performed once in 2 wk or monthly, and their clinical manifestations were recorded. RESULTS: The rate of hepatotoxicity occurred in 26 (59%) TB patients with HBV during anti-TB treatment, higher than that in 40 (24%) TB patients without HBV. Hepatotoxicity occurred in 66 out of 217 patients, and the incidence of liver dysfunction was 46.1% in HPBE(S) group, significantly higher than that in HLAMKO group (12.7%) (P<0.01). CONCLUSION: TB patients with HBV should choose HLAMKO treatment because of fewer hepatotoxicity.
AIM: To observe the effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosispatients with hepatitis B virus (HBV) infection, and to compare the differences of liver function by two treatments of anti-tuberculosis. METHODS: Forty-seven TBpatients with HBV infection and 170 TBpatients without HBV infection were divided into HPBE(S) and HLAMKO treatment groups. Liver function tests before and after the treatments were performed once in 2 wk or monthly, and their clinical manifestations were recorded. RESULTS: The rate of hepatotoxicity occurred in 26 (59%) TBpatients with HBV during anti-TB treatment, higher than that in 40 (24%) TBpatients without HBV. Hepatotoxicity occurred in 66 out of 217 patients, and the incidence of liver dysfunction was 46.1% in HPBE(S) group, significantly higher than that in HLAMKO group (12.7%) (P<0.01). CONCLUSION:TBpatients with HBV should choose HLAMKO treatment because of fewer hepatotoxicity.
Authors: P Sadaphal; J Astemborski; N M Graham; L Sheely; M Bonds; A Madison; D Vlahov; D L Thomas; T R Sterling Journal: Clin Infect Dis Date: 2001-10-12 Impact factor: 9.079
Authors: K Tahaoğlu; G Ataç; T Sevim; T Tärün; O Yazicioğlu; G Horzum; I Gemci; A Ongel; N Kapakli; E Aksoy Journal: Int J Tuberc Lung Dis Date: 2001-01 Impact factor: 2.373
Authors: Mark H Kuniholm; Jennifer Mark; Malvina Aladashvili; N Shubladze; G Khechinashvili; Tengiz Tsertsvadze; Carlos del Rio; Kenrad E Nelson Journal: Int J Infect Dis Date: 2007-07-23 Impact factor: 3.623
Authors: G Bushnell; N L Stennis; A M Drobnik; D C Proops; S D Ahuja; K Bornschlegel; J Fuld Journal: Epidemiol Infect Date: 2014-11-12 Impact factor: 4.434